Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2019 | CAR T-cell therapy toxicities in B-cell lymphomas

Jakub Svoboda • 8 Nov 2019
NCRI 2019
B-Cell Lymphoma Lymphoma

Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, talks about CAR T-cell therapy toxicities in B-cell lymphomas. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

More from Jakub Svoboda

4:40
Engraftment syndrome following ASCT in patients with checkpoint inhibitor treated Hodgkin lymphoma
Jakub Svoboda • 11 Dec 2023
2:54
Everolimus and itacitinib in patients with HL R/R to brentuximab vedotin and checkpoint inhibitors
Jakub Svoboda • 16 Jun 2023
2:48
Incidence and management of peripheral neuropathy in patients with cHL treated with BV + AVD
Jakub Svoboda • 16 Jun 2023
2:54
HuCART19-IL18 in patients with lymphoma previously relapsed/refractory to anti-CD19 CAR-T therapy
Jakub Svoboda • 16 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals